Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study

Fig. 2

Comparisons of signature scores between REM and NON-REM for infliximab (IFX) (a), tocilizumab (TCZ) (b, c), and abatacept (ABT) (d–h). Distributions of the values, mean, and upper and lower limits of 95 % confidence intervals for the mean are shown. p Values were determined using Student’s t test. p < 0.05 was considered statistically significant. REM patients with CDAI remission (defined as CDAI ≤2.8) at 6 months of biologic therapy, NON-REM patients without CDAI remission at 6 months of biologic therapy, CDAI clinical disease activity index, RNA pol II RNA polymerase II, NK natural killer 

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us